More News

Is atherosclerosis an autoimmune disease?

Jim Cornall -
A new study in mice and patients has led to a claim that atherosclerosis meets the criteria for an...

Northway Biotech opens €61m cell therapy and personalised medicine CDMO in Lithuania

Jim Cornall -
The first dedicated cell therapy and personalised medicine centre of its kind in the Baltic states has opened in...

Eascra Biotech receives NASA contract for space-manufactured nanomedicine

Jim Cornall -
Eascra Biotech, a nanomedicine startup with a lab in Worcester, Mass., has been awarded a NASA In Space Production...

Typewriter Therapeutics emerges from stealth with $56m to pursue in vivo CAR T medicines

Jim Cornall -
Typewriter Therapeutics, Inc. has emerged from stealth with $56m in Series A financing. Typewriter is a biotech company developing safe,...

Zifo says CMC bottleneck choking drug pipeline

Jim Cornall -
The biopharma industry has invested heavily in accelerating discovery. AI, machine learning (ML), high-throughput experimentation and advanced modelling are...

How melanoma silences skin’s natural antitumour defence

Jim Cornall -
A new study by researchers from the Atopy (Allergy) Research Center of the Juntendo University Graduate School of Medicine,...

Severe asthma linked to changes in brain structure

Jim Cornall -
People living with a severe form of asthma show subtle differences in the structure of their brains compared with...

New method causes cancer cells to burn out

Jim Cornall -
Researchers at the University of Gothenburg say a new drug forces cancer cells to keep working hard even though...

Convergen raises $15m to advance therapeutics for protein aggregation diseases

Jim Cornall -
Convergen, a biotechnology company creating targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, has announced...

Cancer drug could help millions battling osteoporosis and mid-life weight gain

Jim Cornall -
An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new...

Microdroplets can reduce colorectal tumour growth at lower cost

Jim Cornall -
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing...

Clicklinks launched for drug discovery

Jim Cornall -
Sanyou Biopharmaceuticals Co., Ltd. has launched Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug...

Base to Base biotech podcast 74: A vision for vision, and studying pancreatic cancer

Jim Cornall -
This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell...

FDA first-ever treatment for warm autoimmune haemolytic anaemia

Jim Cornall -
Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY (nipocalimab-aahu) for the treatment...

Rhode Island launches programme to attract life science startups

Jim Cornall -
The Rhode Island Life Science Hub (RILSH) has announced the Founders Compass Program, offered in partnership with Portal Innovations...

Novel drug shows promise in an early phase heart failure trial

Jim Cornall -
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in...

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Jim Cornall -
African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to $16.5m from the...

HiRO and Differentia Biotech look to redefine clinical trial design

Jim Cornall -
At a time when biopharma R&D productivity is declining and the cost of bringing a single drug to market...

Rogue neuronal signal is at the heart of Alzheimer’s disease

admin -
New research suggests a broad range of Alzheimer’s pathologies may be orchestrated by a molecular switch called ERBB4 when...

Aficamten trial positive for patients with non-obstructive hypertrophic cardiomyopathy

Jim Cornall -
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic...

New clues about causes of severe headaches

Jim Cornall -
Inflammation, altered gene regulation, and exposure to substances in tobacco smoke may all contribute to the development of cluster...